FibroGen, Inc. - Product Pipeline Review - 2015

Date: May 27, 2015
Pages: 39
Price:
US$ 1,500.00 US$ 1,200.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: FC735B6D6A7EN
Leaflet:

Download PDF Leaflet

FibroGen, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘FibroGen, Inc. - Product Pipeline Review - 2015’, provides an overview of the FibroGen, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of FibroGen, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides brief overview of FibroGen, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of FibroGen, Inc.’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the FibroGen, Inc.’s pipeline products
Reasons to buy
  • Evaluate FibroGen, Inc.’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of FibroGen, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the FibroGen, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of FibroGen, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of FibroGen, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of FibroGen, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
FibroGen, Inc. Snapshot
FibroGen, Inc. Overview
Key Information
Key Facts
FibroGen, Inc. - Research and Development Overview
Key Therapeutic Areas
FibroGen, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
FibroGen, Inc. - Pipeline Products Glance
FibroGen, Inc. - Late Stage Pipeline Products
Phase III Products/Combination Treatment Modalities
FibroGen, Inc. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
FibroGen, Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
FibroGen, Inc. - Drug Profiles
roxadustat
Product Description
Mechanism of Action
R&D Progress
FG-2216
Product Description
Mechanism of Action
R&D Progress
FG-3019
Product Description
Mechanism of Action
R&D Progress
FG-6874
Product Description
Mechanism of Action
R&D Progress
FG-4497
Product Description
Mechanism of Action
R&D Progress
FG-8205
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Procollagen C-Proteinase for Fibrosis
Product Description
Mechanism of Action
R&D Progress
FibroGen, Inc. - Pipeline Analysis
FibroGen, Inc. - Pipeline Products by Target
FibroGen, Inc. - Pipeline Products by Route of Administration
FibroGen, Inc. - Pipeline Products by Molecule Type
FibroGen, Inc. - Pipeline Products by Mechanism of Action
FibroGen, Inc. - Recent Pipeline Updates
FibroGen, Inc. - Dormant Projects
FibroGen, Inc. - Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

FibroGen, Inc., Key Information
FibroGen, Inc., Key Facts
FibroGen, Inc. - Pipeline by Indication, 2015
FibroGen, Inc. - Pipeline by Stage of Development, 2015
FibroGen, Inc. - Monotherapy Products in Pipeline, 2015
FibroGen, Inc. - Phase III, 2015
FibroGen, Inc. - Phase II, 2015
FibroGen, Inc. - Phase I, 2015
FibroGen, Inc. - Preclinical, 2015
FibroGen, Inc. - Discovery, 2015
FibroGen, Inc. - Pipeline by Target, 2015
FibroGen, Inc. - Pipeline by Route of Administration, 2015
FibroGen, Inc. - Pipeline by Molecule Type, 2015
FibroGen, Inc. - Pipeline Products by Mechanism of Action, 2015
FibroGen, Inc. - Recent Pipeline Updates, 2015
FibroGen, Inc. - Dormant Developmental Projects,2015

LIST OF FIGURES

FibroGen, Inc. - Pipeline by Top 10 Indication, 2015
FibroGen, Inc. - Pipeline by Stage of Development, 2015
FibroGen, Inc. - Monotherapy Products in Pipeline, 2015
FibroGen, Inc. - Pipeline by Top 10 Target, 2015
FibroGen, Inc. - Pipeline by Top 10 Route of Administration, 2015
FibroGen, Inc. - Pipeline by Top 10 Molecule Type, 2015
FibroGen, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Skip to top


AnaptysBio, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Apr, 2015 · 24 pages
EGEN, Inc. - Product Pipeline Review - 2014 US$ 1,125.00 Jul, 2014 · 24 pages
GenSpera, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Aug, 2015 · 27 pages
ImmunoFrontier, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Jun, 2015 · 22 pages
OncoImmune, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Aug, 2015 · 24 pages

Ask Your Question

FibroGen, Inc. - Product Pipeline Review - 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: